Cargando…

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer

BACKGROUND: Combined MET and BRAF inhibition showed clinical benefit in a patient with rectal cancer carrying BRAF(V600E) and MET amplification. However after 4 months, acquired resistance emerged and the patient deceased shortly after disease progression. The mechanism of resistance to this drug co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oddo, Daniele, Siravegna, Giulia, Gloghini, Annunziata, Vernieri, Claudio, Mussolin, Benedetta, Morano, Federica, Crisafulli, Giovanni, Berenato, Rosa, Corti, Giorgio, Volpi, Chiara Costanza, Buscarino, Michela, Niger, Monica, Dunne, Philip D, Rospo, Giuseppe, Valtorta, Emanuele, Bartolini, Alice, Fucà, Giovanni, Lamba, Simona, Martinetti, Antonia, Di Bartolomeo, Maria, de Braud, Filippo, Bardelli, Alberto, Pietrantonio, Filippo, Di Nicolantonio, Federica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537500/ https://www.ncbi.nlm.nih.gov/pubmed/28654634 http://dx.doi.org/10.1038/bjc.2017.196

Ejemplares similares

Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients
por: Crisafulli, Giovanni, et al.
Publicado: (2019)

Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity
por: Bersani, Francesca, et al.
Publicado: (2023)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
por: Van Emburgh, Beth O., et al.
Publicado: (2016)

Role of cMET in the Development and Progression of Colorectal Cancer
por: Pérez-Vargas, Juan Carlos Samamé, et al.
Publicado: (2013)

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies
por: Russo, Mariangela, et al.
Publicado: (2018)

Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study
por: Fucà, Giovanni, et al.
Publicado: (2022)

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy
por: Morano, Federica, et al.
Publicado: (2019)

Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase
por: Falvella, Felicia Stefania, et al.
Publicado: (2015)

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study
por: Pietrantonio, Filippo, et al.
Publicado: (2016)

Prognostic impact of ATM mutations in patients with metastatic colorectal cancer
por: Randon, Giovanni, et al.
Publicado: (2019)

Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2016)

Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases
por: Siravegna, Giulia, et al.
Publicado: (2017)

Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance
por: Amodio, Vito, et al.
Publicado: (2023)

The landscape of d16HER2 splice variant expression across HER2-positive cancers
por: Volpi, Chiara Costanza, et al.
Publicado: (2019)

Author Correction: The landscape of d16HER2 splice variant expression across HER2-positive cancers
por: Volpi, Chiara Costanza, et al.
Publicado: (2020)

Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients
por: Crisafulli, Giovanni, et al.
Publicado: (2022)

Author response to Colle et al
por: Fucà, Giovanni, et al.
Publicado: (2021)

miR‐205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling
por: Migliore, Cristina, et al.
Publicado: (2018)

Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan
por: Pietrantonio, Filippo, et al.
Publicado: (2020)

Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis
por: Cremolini, Chiara, et al.
Publicado: (2017)

Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective
por: Prisciandaro, Michele, et al.
Publicado: (2022)

Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient
por: Milione, Massimo, et al.
Publicado: (2017)

Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study
por: Cremolini, Chiara, et al.
Publicado: (2017)

IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients
por: Di Salvatore, Mariantonietta, et al.
Publicado: (2017)

Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens
por: Martinetti, Antonia, et al.
Publicado: (2014)

Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
por: Fucà, Giovanni, et al.
Publicado: (2021)

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer
por: Di Bartolomeo, Maria, et al.
Publicado: (2015)

Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study
por: Cremolini, Chiara, et al.
Publicado: (2019)

Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O(6)-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial
por: Morano, Federica, et al.
Publicado: (2022)

A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells
por: Russo, Mariangela, et al.
Publicado: (2022)

Editorial: The impact of genetics on CRC therapy: from adaptive mutability to drug resistance
por: Crisafulli, Giovanni, et al.
Publicado: (2023)

The Landscape of Actionable Gene Fusions in Colorectal Cancer
por: Pagani, Filippo, et al.
Publicado: (2019)

BRAF-mutated metastatic colorectal cancer between past and future
por: Cremolini, Chiara, et al.
Publicado: (2015)

Chemotherapy or Targeted Therapy as Second-Line Treatment of Advanced Gastric Cancer. A Systematic Review and Meta-Analysis of Published Studies
por: Iacovelli, Roberto, et al.
Publicado: (2014)

Characterizing the roles of Met31 and Met32 in coordinating Met4-activated transcription in the absence of Met30
por: Carrillo, Emilio, et al.
Publicado: (2012)

Everolimus induces Met inactivation by disrupting the FKBP12/Met complex
por: Raimondo, Lucia, et al.
Publicado: (2016)

HGF/MET and the Immune System: Relevance for Cancer Immunotherapy
por: Papaccio, Federica, et al.
Publicado: (2018)

Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study
por: Raimondi, A., et al.
Publicado: (2021)

HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
por: Pietrantonio, Filippo, et al.
Publicado: (2023)

Critical Role of MetR/MetB/MetC/MetX in Cysteine and Methionine Metabolism, Fungal Development, and Virulence of Alternaria alternata
por: Gai, Yunpeng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kipeoiuqpf6k0mfvv8ll1rfg00